Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This study will test the safety of MSLN-targeted CAR-T cells at different doses to find the
safest dose to give to people with MPM. The researchers want to see what effects, if any, the
study treatment has on people with this type of cancer. This study is the first time that an
MSLN-targeted CAR-T cell treatment with an anti-PD1 component is being given to people.